NEW HAVEN, Conn., April 4, 2024 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic.
Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET
NEW HAVEN, Conn., Feb. 6, 2024 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical.
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.
Operator: Good afternoon and welcome to the Trevi Therapeutics’ Q1 2023 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.